Additionally, the preliminary results from the ALASCCA trial, a multicenter Nordic RCT, demonstrated an over 50% reduction in CRC recurrence in aspirin users when examining patients with PIK3CA-mutated CRCs [50]. This evidence concerns the gene PIK3CA and colorectal carcinoma.